Renal carcinoma, which is a type of kidney cancer, poses notable issues in research and therapeutics, especially in relation to uncommon kidney diseases. Such rare diseases need accurate tools and models that simulate the disease states as closely as possible. Protheragen's renal carcinoma cell line development service creates high-quality and dependable cell lines that aid in rare kidney disease research and is dedicated to developing such cell lines.
Introduction to Renal Carcinoma Cell Line
Renal carcinoma cell lines are cell cultures created from the malignant tumors of kidneys, particularly renal cell carcinomas. They are vital for cancer research since these cell lines serve as stable and reproducible in vitro systems to study various aspects of kidney cancers. Furthermore, they can be used to study the molecular mechanisms of renal carcinogenesis, metastasis, and drug resistance phenotypes because they possess most of the genetic and phenotypic traits of the original tumors.
Fig.1 GPX4 immunostaining of human renal cell carcinoma (RCC) tissue array. (Chang, I., et al., 2021)
Applications of Renal Carcinoma Cell Lines
Cancer Biology and Mechanistic Studies
The renal carcinoma cell lines are invaluable in studying the underlying biology of kidney cancer. They serve as uniform, controllable systems in which cellular activities like proliferation, apoptosis, angiogenesis, metastasis, and tumor microenvironment interactions can be studied.
Drug Discovery and Therapeutic Development
In the development and discovery of new therapies, these cell lines are very important. In vitro, renal carcinoma cell lines are used in high-throughput screening assays to test for the efficacy and toxicity of anticancer compounds. Tumor inhibiting novel drugs and other therapeutic agents are tested on these cell lines to evaluate whether they successfully inhibit tumor growth.
Biomarker Identification
Renal carcinoma cell lines have an essential role in the discovery and validation of biomarkers for diagnosis, prognosis, and monitoring of therapy. These cell lines can be analyzed using genomic, transcriptomic, and proteomic methods to reveal specific gene expression patterns and protein markers that characterize different subtypes of renal carcinoma.
Our Services
Protheragen taps into the latest technologies to customize renal carcinoma cell lines derived from human or animal kidney tumors. These customized cell lines are critical for supporting research and drug development aimed at rare kidney diseases as the cells preserve certain mutational, phenotypic, and molecular specific characteristics of renal carcinoma cells.
Renal Carcinoma Cell Line Development Workflow
Tissue Acquisition and Processing
Obtaining renal carcinoma tissue samples from patient biopsies or xenograft models, followed by enzymatic or mechanical dissociation to generate single-cell suspensions.
Primary Cell Isolation
Enriching malignant renal epithelial cells using density gradient centrifugation, fluorescence-activated cell sorting (FACS), or immunomagnetic bead-based techniques targeting tumor-specific surface markers.
Culture Optimization
Establishing growth conditions with selective media, growth factors, and stromal co-culture or 3D matrices to suppress fibroblast overgrowth and maintain tumorigenic properties.
Validation and Characterization
Confirming clonal origin via STR profiling, validating oncogenic mutations, and assessing in vitro/in vivo tumorigenicity through xenograft assays and functional pathway analyses.
Renal Carcinoma Cell Line Development for Rare Kidney Cancers
With profound knowledge accumulated over years, Protheragen offers a spectrum of services for the development of renal carcinoma cell lines, meticulously crafted to satisfy the specific parameters of your investigation. Due to our extensive experience in kidney cancer modeling, we specialize in addressing the unique challenges of rare renal carcinoma subtypes, delivering innovative and precise solutions to advance your research objectives.
- Clear Cell Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- Chromophobe Renal Cell Carcinoma
- Collecting Duct Carcinoma
- Renal Medullary Carcinoma
- Wilms Tumor
- MITF/TFE3 Translocation Renal Cell Carcinoma
- Sarcomatoid Renal Cell Carcinoma
Why Choose Us?
Professional core technical team.
Advanced experimental equipment.
Empowering success through cooperation.
Strict quality control system.
At Protheragen, we are dedicated to offering comprehensive, one-stop preclinical development services, specializing in renal carcinoma cell line development for kidney disease research. From diseases model development to drug safety evaluation, our services support every stage of your research process. If you are interested in our services, please don't hesitate to contact us.
References
- Chang, I., et al. "Snu-333 Cells as an Appropriate Cell Line for the Orthotopic Renal Cell Carcinoma Model." Technol Cancer Res Treat 20 (2021): 15330338211038487.
- Wang, Y., et al. "Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma and Associated Opportunities for Therapeutics." Br J Pharmacol 180.23 (2023): 2937-55.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
